Key statistics
On Friday, Allogene Therapeutics Inc (ALLO:NSQ) closed at 2.21, 11.06% above the 52 week low of 1.99 set on Nov 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.12 |
---|---|
High | 2.23 |
Low | 2.09 |
Bid | 2.25 |
Offer | 2.28 |
Previous close | 2.11 |
Average volume | 2.53m |
---|---|
Shares outstanding | 209.67m |
Free float | 151.68m |
P/E (TTM) | -- |
Market cap | 442.41m USD |
EPS (TTM) | -1.53 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Allogene Therapeutics Announces Participation in December Investor Conferences
- Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
- Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
- Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
- Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Allogene Therapeutics Announces Participation in November Investor Conferences
- Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
- Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
- Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
- Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
More ▼